A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

PubWeight™: 19.14‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMID 26551272)

Published in N Engl J Med on November 09, 2015

Authors

SPRINT Research Group, Jackson T Wright, Jeff D Williamson, Paul K Whelton, Joni K Snyder, Kaycee M Sink, Michael V Rocco, David M Reboussin, Mahboob Rahman, Suzanne Oparil, Cora E Lewis, Paul L Kimmel, Karen C Johnson, David C Goff, Lawrence J Fine, Jeffrey A Cutler, William C Cushman, Alfred K Cheung, Walter T Ambrosius

Associated clinical trials:

Systolic Blood Pressure Intervention Trial (SPRINT) | NCT01206062

Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) | NCT03015311

Hypertension in Long-Term Care Facilities | NCT03046420

SPRINT Trial Type Blood Pressure Measurements in Patients After Kidney Transplantation | NCT03094702

Uncontrolled Hypertension Management (TEAM-HTN) (TEAM-HTN) | NCT03281772

Comparison of Blood Pressure Measurement With an Omron HEM-907 Device in a Clinical Setting and a Research Setting (OMRONHEM-907) | NCT03360669

Blood Pressure Lowering in Dialysis (BOLD) Trial (BOLD) | NCT03459807

Hypertension Management in Family Practice | NCT03579108

Wrist-based Blood Pressure Monitoring Study | NCT03661112

TEC4Home Stroke - Feasibility of Home Telemonitoring Technology in Managing Hypertension Among Stroke/TIA Patients | NCT03712033

Water-only Fasting in the Treatment of Hypertension Patients | NCT04515095

Articles citing this

(truncated to the top 100)

Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. JAMA (2016) 5.67

Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation (2017) 2.76

Redefining Blood-Pressure Targets--SPRINT Starts the Marathon. N Engl J Med (2015) 2.30

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (2016) 2.25

2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J (2016) 2.09

Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke-Blood Pressure) randomised controlled trial. BMJ (2016) 2.05

Time for a prepublication culture in clinical research? Lancet (2015) 1.90

Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation (2016) 1.69

Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. BMJ (2016) 1.50

Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ (2016) 1.30

SPRINT to evidence for specific blood pressure targets. Can Fam Physician (2016) 1.08

Research Needs to Improve Hypertension Treatment and Control in African Americans. Hypertension (2016) 0.99

Longitudinal Patterns of Blood Pressure, Incident Cardiovascular Events, and All-Cause Mortality in Normotensive Diabetic People. Hypertension (2016) 0.98

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology (2016) 0.98

Intensive lowering of blood pressure: Should we SPRINT? CMAJ (2016) 0.96

Cardiovascular Disease in Women: Clinical Perspectives. Circ Res (2016) 0.92

Intensive vs Standard Blood Pressure Control for Older Adults. JAMA (2016) 0.91

CD70 Exacerbates Blood Pressure Elevation and Renal Damage in Response to Repeated Hypertensive Stimuli. Circ Res (2016) 0.91

Activation of Human T Cells in Hypertension: Studies of Humanized Mice and Hypertensive Humans. Hypertension (2016) 0.89

Age and Outcomes Associated with BP in Patients with Incident CKD. Clin J Am Soc Nephrol (2016) 0.87

Treatment Intensification for Hypertension in US Ambulatory Medical Care. J Am Heart Assoc (2016) 0.87

Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension (2016) 0.87

Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome (2017) 0.87

Timeline of History of Hypertension Treatment. Front Cardiovasc Med (2016) 0.86

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2016) 0.84

Low-Salt Diet and Circadian Dysfunction Synergize to Induce Angiotensin II-Dependent Hypertension in Mice. Hypertension (2016) 0.84

Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study. Hypertension (2016) 0.84

Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation (2016) 0.84

Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey). Circulation (2017) 0.84

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2016) 0.83

Blood Pressure-Related Outcomes in a Diabetic Population. Hypertension (2016) 0.83

Hypertension: Cardiovascular benefits of lowering blood pressure. Nat Rev Nephrol (2016) 0.83

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2016) 0.83

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2016) 0.83

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2016) 0.83

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2016) 0.83

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2016) 0.83

Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study. Diabetes Care (2016) 0.83

US Hypertension Management Guidelines: A Review of the Recent Past and Recommendations for the Future. J Am Heart Assoc (2015) 0.82

Telemonitoring and Protocolized Case Management for Hypertensive Community-Dwelling Seniors With Diabetes: Protocol of the TECHNOMED Randomized Controlled Trial. JMIR Res Protoc (2016) 0.82

Evidence to Maintain the Systolic Blood Pressure Treatment Threshold at 140 mm Hg for Stroke Prevention: The Northern Manhattan Study. Hypertension (2016) 0.82

Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study. Am J Hypertens (2016) 0.82

APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume. Kidney Int (2016) 0.81

BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol (2016) 0.81

What to say and how to say it: effective communication for cardiovascular disease prevention. Curr Opin Cardiol (2016) 0.81

A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. Alzheimers Res Ther (2016) 0.81

Longitudinal Patterns of Change in Systolic Blood Pressure and Incidence of Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. Hypertension (2016) 0.81

A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence. J Gen Intern Med (2017) 0.81

Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (2017) 0.80

Alternative Strategies to Achieve Cardiovascular Mortality Goals in China and India: A Microsimulation of Target- Versus Risk-Based Blood Pressure Treatment. Circulation (2016) 0.80

Longitudinal Trends in Hypertension Management and Mortality Among Octogenarians: Prospective Cohort Study. Hypertension (2016) 0.80

Ambulatory Blood Pressure Monitoring in Chinese Obstructive Sleep Apnea Patients. J Clin Sleep Med (2016) 0.80

Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control. J Am Coll Cardiol (2016) 0.80

Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool. J Am Coll Cardiol (2016) 0.80

Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy. Circulation (2016) 0.80

The year in cardiology 2015: prevention. Eur Heart J (2016) 0.79

Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc (2016) 0.79

Is 60 the New 80 in Hypertension? J Gen Intern Med (2016) 0.79

The results of a survey of physicians about the Japanese Society of Hypertension Guidelines for the Management of Hypertension 2014 and its clinical use. Hypertens Res (2016) 0.79

Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension. Hypertens Res (2016) 0.79

Implications of Blood Pressure Measurement Technique for Implementation of Systolic Blood Pressure Intervention Trial (SPRINT). J Am Heart Assoc (2017) 0.78

Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burden. BMC Cardiovasc Disord (2016) 0.78

Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups: Age <50 Years, Diabetes Mellitus, or a History of Stroke. J Am Heart Assoc (2016) 0.78

Stroke Risk Factors, Genetics, and Prevention. Circ Res (2017) 0.78

Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease. Kidney Int (2016) 0.78

Hypertension in Chronic Glomerulonephritis. Electrolyte Blood Press (2015) 0.78

Systolic blood pressure and cardiovascular mortality in middle-aged and elderly adults - The Singapore Chinese Health Study. Int J Cardiol (2016) 0.78

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2016) 0.78

Association between insufficient medication of antihypertensives and the severity of acute ischemic stroke. Clin Hypertens (2016) 0.78

SPS3 Evidence Supports Intensive Blood Pressure Control. Circulation (2016) 0.78

Adherence to Antihypertensive Therapy. Med Clin North Am (2017) 0.78

Effects of Intensive BP Control in CKD. J Am Soc Nephrol (2017) 0.78

Usefulness of Left Ventricular Mass and Geometry for Determining 10-Year Prediction of Cardiovascular Disease in Adults Aged >65 Years (from the Cardiovascular Health Study). Am J Cardiol (2016) 0.77

Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis (2017) 0.77

Controlling Hypertension to Prevent Target Organ Damage: Perspectives from the World Hypertension League President. Ethn Dis (2016) 0.77

Hypertension in Russia: Changes Observed After 4 Years of a Comprehensive Health System Improvement Program in the Yaroslavl Region. J Clin Hypertens (Greenwich) (2016) 0.77

Current and Future Treatment of Hypertension in the SPRINT Era. Methodist Debakey Cardiovasc J (2016) 0.77

Intima-Media Thickness Is Linearly and Continuously Associated With Systolic Blood Pressure in a Population-Based Cohort (STANISLAS Cohort Study). J Am Heart Assoc (2016) 0.77

Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions. Am J Nephrol (2016) 0.77

The J-Curve Phenomenon in Hypertension. Pulse (Basel) (2016) 0.77

Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance. Hypertension (2016) 0.77

Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients with Hypertension: The Systolic Blood Pressure Intervention (SPRINT) Trial. Circulation (2017) 0.77

Managing Hypertension in the Elderly: What is Different, What is the Same? Curr Hypertens Rep (2017) 0.76

Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill. Curr Hypertens Rep (2016) 0.76

Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China. BMC Health Serv Res (2016) 0.76

Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease: Results From the US Cohort of the International Verapamil (SR)/Trandolapril Study. Hypertension (2016) 0.76

Heart failure in 2015: Better results from prevention than from additional treatment. Nat Rev Cardiol (2016) 0.76

Progression of Chronic Kidney Disease After Acute Kidney Injury: Role of Self-Perpetuating Versus Hemodynamic-Induced Fibrosis. Hypertension (2016) 0.76

Prevention of stroke: a strategic global imperative. Nat Rev Neurol (2016) 0.76

The metabolic vascular syndrome - guide to an individualized treatment. Rev Endocr Metab Disord (2016) 0.76

LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. J Hypertens (2016) 0.76

Role of Dietary Components in Modulating Hypertension. J Clin Exp Cardiolog (2016) 0.76

Midlife Cardiovascular Risk Factors and Late-Life Unrecognized and Recognized Myocardial Infarction Detect by Cardiac Magnetic Resonance: ICELAND-MI, the AGES-Reykjavik Study. J Am Heart Assoc (2016) 0.76

Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model. Hypertension (2016) 0.76

Trends in Antihypertensive Medication Discontinuation and Low Adherence Among Medicare Beneficiaries Initiating Treatment From 2007 to 2012. Hypertension (2016) 0.76

Emerging Concepts in the Diagnosis and Treatment of Hypertension in the SPRINT Era. Methodist Debakey Cardiovasc J (2016) 0.75

Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity. Intern Emerg Med (2016) 0.75

William B. White Explains the Changes In the Way We Look at Blood Pressure: Which Numbers Matter Most-and Why Can They Be Deceptive? P T (2016) 0.75

Global cardiovascular protection in chronic kidney disease. Nat Rev Cardiol (2016) 0.75

A Novel Approach for Estimating Cost-Effectiveness of Pharmacological Treatment in Drug Naïve Adults with Hypertension. Am J Hypertens (2016) 0.75

Articles cited by this

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 50.94

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 36.26

Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76

Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12

Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 24.72

Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49

Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA (1991) 14.36

Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med (2001) 10.54

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet (2000) 9.78

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet (1997) 9.18

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet (2005) 9.00

The progression from hypertension to congestive heart failure. JAMA (1996) 7.56

Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25

Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA (1997) 5.91

Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet (2013) 5.20

Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med (2014) 3.81

The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials (2014) 3.50

Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief (2013) 3.35

The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens (2005) 3.27

Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension (2001) 3.16

Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension (2006) 3.02

Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med (2005) 2.90

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med (2000) 2.83

Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res (2008) 2.74

Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension (2010) 2.37

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care (2014) 2.20

A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int (1997) 1.76

Cardiovascular risks related to increased diastolic, systolic and pulse pressure. An epidemiologist's point of view. Pathol Biol (Paris) (1999) 1.43

Articles by these authors

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37

Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78

Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90

Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18

Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49

Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58

Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35

A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22

Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci (2004) 12.46

Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44

Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09

Major causes of death among men and women in China. N Engl J Med (2005) 11.80

Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75

In-center hemodialysis six times per week versus three times per week. N Engl J Med (2010) 10.73

Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med (2002) 10.52

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24

Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06

Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62

MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet (2008) 9.50

Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20

MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet (2008) 9.00

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90

Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74

Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73

Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64

Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48

Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19

Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14

Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA (2002) 7.93

The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79

Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ (2007) 7.54

Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA (2008) 7.50

The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49

Association of weight status with mortality in adults with incident diabetes. JAMA (2012) 7.49

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA (2013) 7.19

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96

Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol (2008) 6.91

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 6.87

Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol (2006) 6.86

Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66

Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63

Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51

Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum (2004) 6.46

Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA (2012) 6.29

Worldwide prevalence of hypertension: a systematic review. J Hypertens (2004) 6.25

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03

Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00

Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol (2007) 6.00

Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med (2005) 5.78

Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. JAMA (2016) 5.67

Racial differences in incident heart failure among young adults. N Engl J Med (2009) 5.60

Smoking and mortality--beyond established causes. N Engl J Med (2015) 5.54

The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med (2004) 5.45

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA (2004) 5.35

Effects of low-carbohydrate and low-fat diets: a randomized trial. Ann Intern Med (2014) 5.31

Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation (2011) 5.26

Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26

Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22

Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation (2007) 5.20

Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA (2012) 5.15

The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14

Prevalence of the metabolic syndrome and overweight among adults in China. Lancet (2005) 5.05

High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00

APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med (2013) 5.00

Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84